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Abstract
Background: To evaluate clinical outcomes of simultaneous integrated boost (SIB) - intensity modulated
radiotherapy (RT) in patients with non metastatic anal cancer compared to those of a set of patients treated with 3-
dimensional conformal RT and sequential boost (SeqB).
Methods: A retrospective cohort of 190 anal cancer patients treated at 3 academic centers with concurrent chemo-
RT employing either SIB or SeqB was analysed. The SIB-group consisted of 87 patients, treated with 2 cycles of
Mitomycin (MMC) and 5-Fluorouracil (5FU) using SIB-IMRT delivering 42-45Gy/28–30 fractions to the elective pelvic
lymph nodes and 50.4-54Gy/28-30fractions to the primary tumor and involved nodes, based on pre-treatment
staging. The SeqB group comprised 103 patients, treated with MMC associated to either 5FU or Capecitabine
concurrent to RT with 36 Gy/20 fractions to a single volume including gross tumor, clinical nodes and elective
nodal volumes and a SeqB to primary tumor and involved nodes of 23.4 Gy/13 fractions. We compared colostomy-
free survival (CFS), overall survival (OS) and the cumulative incidence of colostomy for each radiation modality. Cox
proportional-hazards model addressed factors influencing OS and CFS.
Results: Median follow up was 34 (range 9–102) and 31 months (range 2–101) in the SIB and SeqB groups. The 1-
and 2-year cumulative incidences of colostomy were 8.2% (95%CI:3.6–15.2) and 15.0% (95%CI:8.1–23.9) in the SIB
group and 13.9% (95%CI: 7.8–21.8) and 18.1% (95%CI:10.8–27.0) in the SeqB group. Two-year CFS and OS were 78.
1% (95%CI:67.0–85.8) and 87.5% (95%CI:77.3–93.3) in the SIB group and 73.5% (95%CI:62.6–81.7) and 85.4% (95%CI:
75.5–91.6) in the SeqB, respectively. A Cox proportional hazards regression model highlighted an adjusted hazard
ratio (AdjHR) of 1.18 (95%CI: 0.67–2.09;p = 0.560), although AdjHR for the first 24 months was 0.95 (95%CI: 0.49–1.84;
p = 0.877) for the SIB approach.
Conclusions: SIB-based RT provides similar clinical outcomes compared to SeqB-based in the treatment of patients
affected with non metastatic anal cancer.
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Background
Concurrent chemo-radiation (RT-CHT) is presently con-
sidered as a standard therapeutic option in patients af-
fected with squamous cell carcinoma of the anal canal
[1, 2]. The association of pelvic radiotherapy (RT) to
concomitant 5-fluorouralcil (5-FU) and mitomycin C
provides high rates of complete responders (around
90%) and consistent results in terms of disease-free sur-
vival (DFS), up to 70–75% for early disease (T1-T2 tu-
mors) and 60–65% for more advanced stages (T3-T4 or
node positive tumors) at 3 years [2–4]. When RT is de-
livered with conventional techniques, the toxicity profile
can be important, as observed in the 5-FU/MMC arm of
the RTOG 9811 trial, with grade 3–4 events as high as
48% for skin and 61% for hematologic toxicity [5]. As a
result, treatment breaks can be necessary with a pro-
longation of overall treatment time (OTT) and conse-
quent detrimental effects on clinical outcomes [6].
Intensity-modulated radiotherapy was shown to reduce
the rates of ≥ G3 acute gastrointestinal and skin toxicity
and that of ≥ G2 hematologic events [7, 8]. Moreover,
oncological results in terms of both local control (LC)
colostomy-free (CFS) and overall survival (OS) seems
promising with this treatment strategy [9, 10]. In anal
cancer patients, macroscopic primary and nodal disease
and elective volumes are treated to different total nom-
inal doses [11]. In the sequential boost approach (SeqB),
this can be achieved through the progressive boosting of
selected target regions harboring the macroscopic dis-
ease [12]. Target volumes are progressively shrinking
and boost dose is added on top of the previous sequence
[13]. In the simultaneous integrated boost (SIB) strategy,
a differential dose per fraction is delivered to selected
sub-regions during the same treatment session, heading
to different total nominal doses given to target volumes
in the same number of fractions [1]. Consequently, SIB
provides a reduction in OTT compared to the sequential
boost approach, with a potential beneficial effect on clin-
ical outcomes in the context of a highly repopulating
tumor such as anal cancer [14]. To evaluate the potential
impact of different treatment strategies on clinical out-
comes, we compared data of 2 cohorts of anal cancer
patients treated either with SeqB or SIB approaches, in
terms of CFS as primary endpoint, after adjusting for
known prognostic factors, and in terms of OS and cu-
mulative incidence of colostomy as secondary endpoints.
Methods
In this multi-centre retrospective observational study,
we compared clinical outcomes of patients affected with
anal cancer. Consecutive patients treated between 2007
and 2015 at the Radiation Oncology Departments of 3
academic Institutions were enrolled, namely a) Univer-
sity of Turin, Italy, b) University Hospital ‘Jean Minjoz’,
Besançon, France and c) Centre ‘Georges François
Leclerc’, Dijon, France. Clinical data were retrieved from
local clinical databases by 2 different operators (FA and
AL) and merged together on a common database used
for the present analysis. The frame of the final dataset
was agreed by the 2 centres. Briefly, all patients enrolled
had a histologically confirmed diagnosis of anal squa-
mous cell carcinoma (both anal canal and margin).
Tumor stage was defined according to the indications of
the American Joint Committee on Cancer (2002 version)
and patients with clinical stage T1-T4, N0-N3, M0 were
included. Patients having clinical T1 N0 tumors of the
anal margin were excluded, because they were submitted
to local excision. Pre-treatment clinical evaluation in-
cluded complete medical history, physical examination
and complete laboratory testing. Staging included a
chest, abdomen and pelvis computed tomography scan
(CT), a magnetic resonance imaging (MRI) of the pelvic
region and positron-emission tomography (PET). A sub-
set of patients within the SIB group, treated in center a),
also received inguinal sentinel lymphnode biopsy (SLNB)
for inguinal nodal staging. Patients in the SeqB, treated
in centres b) and c), did not receive any SLNB procedure
because of a different staging policy. Patients were
followed-up according to local clinical practice and vital
status was clinically updated in 2016. Written informed
consent for treatment was obtained for all patients. The
Ethical Review Board of each Institutional Hospital ap-
proved the present study.
Radiotherapy characteristics
In the SeqB group, including patients treated in centres
b) and c) between 2007 and 2015, the first sequence of
treatment included the delivery of 36 Gy in 20 fractions
(1.8 Gy daily) given over 4 weeks to the macroscopic pri-
mary and nodal tumor and elective volumes including
the ischio-anal fossa and mesorectum, the pre-sacral, ex-
ternal and internal iliac nodes, the inguinal regions and
the lower part of the common iliac lymphnodes up to
the promontorium. After the first sequence a 16-day gap
was planned. In the second sequence, an adjunctive dose
of 23.4 Gy in 13 fractions was given to the macroscopic
disease which finally received a total nominal dose of
59.4 Gy. In the SIB group, including patients treated in
centre a) in the period 2007–2015, dose prescription was
set according to the RTOG 0529 indications based on
clinical stage at presentation [6]. Patients with cT2N0
disease were given 50.4 Gy in 28 fractions (1.8 Gy daily)
to the primary anal tumor, while the elective nodal vol-
ume was prescribed 42 Gy in 28 fractions (1.5 Gy/daily).
Patients presenting cT3-T4/N0-N3 disease were pre-
scribed 54 Gy in 30 fractions (1.8 Gy daily) to the gross
tumor volume, while gross nodal disease was prescribed
50.4 Gy in 30 fractions (1.68 Gy daily) if sized ≤ 3 cm or
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54 Gy in 30 fractions (1.8 Gy daily) if > 3 cm. Elective
nodal volume was prescribed 45 Gy in 30 fractions
(1.5 Gy daily) [15, 16] . No brachytherapy boost was
given to any patient in either group.
Chemotherapy characteristics
In the SIB group, concomitant chemotherapy (CHT)
consisted of 5- fluorouracil (1000 mg/m2/day) given as
continuous infusion for 96 h (days 1–5 and 29–33) com-
bined with mitomycin C (10 mg/m2) given as bolus
(days 1 and 29). A total of 2 concurrent cycles were
planned for each patient. In the SeqB group, at day 1 of
each sequence, mitomycin C (10 mg/m2) was associated
either with continuous infusion 5- fluorouracil
(1000 mg/m2/day) over 96 h or capecitabine (825 mg/m2
bid on weekdays). Capecitabine has been used only for
patients treated in centres b) and c).
Statistical analysis
The primary study endpoint was CFS defined as the time
between RT start and the date of colostomy, death, or
last follow-up date on which the patient was known to
be colostomy-free. Secondary endpoints were OS and
cumulative incidence of colostomy. Overall survival was
defined as the time between RT beginning and the date
of death from any cause or last follow-up. Cumulative
incidence of colostomy was calculated considering death
from any cause as competing event. The number of anal
cancer cases in the 3 Institutions during the study period
determined the sample size. No treated patient was ex-
cluded from the present analysis and hence about 200
patients were analysed. For each cohort, the
time-to-event functions of CFS and OS were estimated
by the Kaplan-Meier product-limit method. Hazard Ra-
tios (HRs) for the treatment group comparison were es-
timated using univariable and multivariable Cox
proportional-hazards models, adjusting in the multivari-
able analysis for the main prognostic factors. The follow-
ing variables were included in the multivariate analysis:
treatment (SIB vs SeqB), gender, age as continuous vari-
able, clinical stage (stage III vs stage I and II), and grade
(G3 vs G1-G2). In order to check for the
proportional-hazards assumption, we performed the
Grambsch and Therneau test [17]. Although the as-
sumption was satisfied for CFS (p = 0.37), we assessed
the time-varying effect of treatment in the Cox model,
according to 2 follow-up periods: the first 24 months
after treatment and the timespan from 24 months to the
end of follow-up. Considering the graphical representa-
tion of CFS, the two-year time-point was chosen because
corresponding to an effect modification of treatments
over time. To take into account the occurrence of death
as a competing event during time, the cumulative risk of
colostomy was estimated using the method described by
Gooley et al. [18]. Difference between cohorts was
assessed using univariable and multivariable (adjusting
for the same variables used for CFS and OS) Fine &
Gray models [19]. For all the endpoints, adjusted ana-
lyses were also performed including a propensity score
(PS) in the regression models along with the treatment
group variable. The PS for the likelihood of receiving the
SIB treatment was calculated using a logistic regression
model that included the same variables used in the mul-
tivariable analysis.
Because of the retrospective nature of the study, no tox-
icity data were retrieved apart from hematologic toxicity
which was considered as reliably exploitable . Hematologic
toxicity was scored according to the RTOG scoring scale.
Results
A total of 190 patients were retrieved. The SIB group
(center a) included 87 patients, while the SeqB group
comprised of 103 cases (centres b and c). Detailed charac-
teristics and comparative evaluation can be found in
Table 1. Patients in the SeqB had a significant higher rate
of anal margin localization (22.3% vs 16.1%; p < 0.0001),
positive lymphnodes (48.5% vs 34.5%; p = 0.0015), inguinal
groin involvement at diagnosis (35.9% vs 20.7%; p =
0.0187), and G3 differentiation (24.1% vs 16.5%; p =
0.0003). Borderline significant difference was found for ad-
vanced global stage (IIIA-IIIB: 54.4% vs 38.0%; p = 0.0730)
and T-stage (T3-T4: 40.8% vs 31.0%;p = 0.0725) between
SeqB and SIB groups (Table 1).
Patients in the SIB group had a significantly higher pro-
portion of patients with a longer time between biopsy and
RT start (patient with time ≥ 60 days: 66.7% vs 49.5%; p =
0.0172). This was due to the inguinal SLNB procedure
that was performed in some of the patients in the SIB
group, which required extra time for the healing of the
surgical scar. Median biopsy-RT time was 74 days (IQR:
54–98) in the SIB and 59 days (IQR: 45–73) in the SeqB
groups. Median OTT (time from RT start to end) was
43 days (IQR: 42–45) in the SIB and 60 days (IQR: 58–63)
in the SeqB groups. The proportion of patients with
OTT ≥ 45 days was significantly higher (95.1% vs 28.7%; p
< 0.0001) in the SeqB group. In the SeqB, 5 patients re-
ceived only the first sequence of treatment because of
major acute toxicity (OTT range: 28–32 days). Treatment
characteristics are shown in Table 2.
Pattern of failure, colostomy rates and survival
Median observation times were 34 (range 9–102) and
31 months (range 2–101) in the SIB and SeqB groups,
respectively. However, out of 103 patients, 17 (16.5%) in
the SeqB group were lacking of updated observation
(last follow up between 1 and 4 years from analysis). In
the SeqB group, the pattern of failure comprised 21
(20.4%) local, 8 (7.8%) nodal and 6 (5.8%) distant
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relapses. In the SIB group, local failures were 16 (18.4%),
nodal 6 (6.9%) and distant 13 (14.9%). Overall, 12 colos-
tomies (13.8%) were observed in the SIB and 17 (16.5%) in
the SeqB groups, respectively. In the SIB group all colos-
tomies were due to salvage surgery done because of local
relapse. In the SeqB group all colostomies except one were
due to salvage procedures. Only 1 colostomy was per-
formed at 52 months because of functional issues.
The 1- and 2-year cumulative incidence of colostomies
were 8.2% (95%CI: 3.6–15.2) and 15.0% (95%CI: 8.1–
23.9) in the SIB group and 13.9% (95%CI: 7.8–21.8) and
18.1% (95%CI: 10.8–27.0) in the SeqB group (Fig. 1).
Two-year CFS and OS were 78.1% (95%CI: 67.0–85.8)
and 87.5% (95%CI: 77.3–93.3) in the SIB group and
73.5% (95%CI: 62.6–81.7) and 85.4% (95%CI: 75.5–91.6)
in the SeqB, respectively (Fig. 2). Results from Cox pro-
portional hazards regression models and Fine & Gray
models are shown in Table 3. During the whole
follow-up, SIB radiotherapy had an adjusted hazard ratio
(AdjHR) of 1.18 (95%CI: 0.67–2.09,p = 0.560), although
AdjHR for the first 24 months was 0.95 (95%CI: 0.49–
1.84, p = 0.877) (Fig. 2). No significant differences were
found between groups for OS (AdjHR = 1.51, 95%CI:
Table 1 Patient and tumor characteristics and pattern of failure
Variables SIB group SeqB group Total p-value
Pts N (%) Pts N (%) Pts N (%)
Sex
Female 64 (73.6) 76 (73.8) 140 (73.7) 0.9722
Male 23 (26.4) 27 (26.2) 50 (26.3)
Median age (range) 64 (55–70) 62 (53–77) 63 (53–77) a0.4471
Subsite
Anal canal 73 (83.9) 80 (77.7) 153 (80.5) <.0001
Anal margin 14 (16.1) 23 (22.3) 37 (19.5)
Histologic type
Basaloid 7 (8.0) 7 (6.8) 14 (7.4) 0.7425
Squamous cell 80 (92.0) 96 (93.2) 176 (92.6)
Grading
NA 2 (2.4) 19 (18.4) 21 (11.1)
G1 7 (8.0) 28 (27.2) 35 (18.4) 0.0003
G2 57 (65.5) 39 (37.9) 96 (50.5)
G3 21 (24.1) 17 (16.5) 38 (20.0)
T stage
T1 5 (5.8) 4 (3.9) 9 (4.7) 0.0725
T2 55 (63.2) 57 (55.3) 112 (59.0)
T3 23 (26.4) 25 (24.3) 48 (25.3)
T4 4 (4.6) 17 (16.5) 21 (11.0)
N stage
N0 57 (65.5) 53 (51.5) 110 (57.9) 0.0015
N1 5 (5.8) 17 (16.5) 22 (11.6)
N2 21 (24.1) 15 (14.6) 36 (18.9)
N3 4 (4.6) 18 (17.4) 22 (11.6)
Global stage
I 5 (5.7) 3 (2.9) 8 (4.2) 0.0730
II 49 (56.3) 44 (42.7) 93 (48.9)
IIIA 8 (9.3) 21 (20.4) 29 (15.3)
IIIB 25 (28.7) 35 (34.0) 60 (31.6)
Inguinal node involv.
NA 0 (0%) 1 (1) 1 (0.6) 0.0187
Yes 18 (20.7) 37 (35.9) 55 (28.9)
No 69 (79.3) 65 (63.1) 134 (70.5)
Time biopsy-RT (days)
≥ 60 62 (71.3) 5 (4.9) 67 (35.3) 0.0172
< 60 25 (28.7) 98 (95.1) 123 (64.7)
OTT (days)
< 45 62 (71.3) 5 (4.9) 67 (35.3) <.0001
≥ 45 25 (28.7) 98 (95.1) 123 (64.7)
aU-Mann Whitney Test
Legend: SIB simultaneous integrated boost, SeqB sequential boost, pts patients,
N: number; involv.: Involvement, RT radiotherapy; OTT overall treatment time
Table 2 Treatment characteristics
Variable N (%)
Boost approach
SeqB 103 (54.3)
SIB 87 (45.7)
SIB dose and fractionation
PTV dose-tumor (Gy)
54 Gy/30 fractions 57 (65.5)
50.4 Gy/28 fractions 30 (34.5)
PTV dose-positive nodes (Gy) (26 pts)
50.4 Gy/30 fractions 26 (100.0)
PTV dose-negative nodes (Gy)
45 Gy/30 fractions 53 (60.9)
42 Gy/28 fractions 34 (39.1)
SeqB dose and fractionation
PTV dose-first sequence
36 Gy/20 fractions 103 (100)
PTV dose-sequential boost
23,4 Gy/13 fractions 103 (100)
Chemotherapy regimens
5-FU + MMC × 2 cycles 159 (83.7)
5-FU + MMC × 1 cycle 2 (1.0)
Capecitabine + MMC × 2 cycles 26 (13.7)
Capecitabine + MMC × 1 cycle 3 (1.6)
Legend, SeqB sequential boost, SIB simultaneous integrated boost, PTV
planning target volume, Gy Gray, pts patients, 5-FU 5-fluorouracil, MMC
mitomycin C
Franco et al. Radiation Oncology  (2018) 13:172 Page 4 of 8
0.77–2.98, p = 0.235) and the cumulative incidence of
colostomy (AdjHR = 0.85, 95%CI: 0.39–1.83, p = 0.675).
Treatment comparisons adjusted using the PS approach
showed results nearly identical to those of multivariable
models (Table 3).
No difference (p = 0.65) in terms of ≥G3 hematologic
toxicity was found between the SeqB group (22%) and
the SIB group (26%).
Discussion
Combined RT-CHT in a concomitant setting is the
standard of cancer for anal cancer patients [11]. In Eur-
ope, split-course high-dose RT was mostly chosen as a
treatment option following established seminal works
[20]. A treatment gap was planned between the first
large-field phase and the second boost phase on the
macroscopic disease. The gap was intended to allow for
the resolution of acute skin and mucosa toxicity and for
tumor response assessment to better tailor the subse-
quent overdosage on the residual disease [7]. This ap-
proach was set by 2 randomized phase III trials namely
the ACT I and EORTC 22861 trials, which demonstrated
the benefit of adding CHT over RT alone, in terms of
local control, sphincter preservation rate and overall sur-
vival [21, 22]. In these trials, RT was given employing 2
treatment sequences delivered sequentially. In the
EORTC 22861 trial, 45 Gy over 5 weeks were given
using conventional fractionation to the whole pelvis
followed, after a 6-week interval, by a boost dose modu-
lated according to treatment response (20 Gy to partial
and 15 Gy to complete responders) and delivered thor-
ough photons, electrons or 192Ir implants [21]. Con-
comitant CHT (continuously infused 5-FU and bolus
MMC) was given only during the first treatment se-
quence [21]. Similarly, in the ACT I trial, the first phase
was made up of 45 Gy in 20 or 25 fraction over 4 to
5 weeks, while the boost (given to complete or > 50%
partial responders) employed 15 Gy in 6 fractions with
photons or electrons or 25 Gy given at 10 Gy per day
given with iridium implants [22]. Mitomycin C was
given at the beginning of the first phase and 5-FU at the
beginning and end of it. In the US, clinical researches
mostly employed a moderate dose and continuously de-
livered RT course associated to concurrent chemother-
apy as in the RTOG 8704-ECOG 1289 trial, in which
patients were treated up to 45–50.4 Gy, with field reduc-
tion at 30.6–36 Gy, with concurrent 5-FU ±MMC for
2 cycles [23]. Based on the observation that accelerated
tumor cell repopulation occurs during RT and may have
detrimental effects on clinical outcomes, clinical re-
search started to shorten treatment regimens to decrease
overall treatment time [24]. For example the EORTC
22953 phase II trial, investigated the feasibility and tox-
icity profile of a reduction in the gap period between the
whole pelvis phase and the boost to 2 weeks, together
with the intensification of the CHT regimen [25]. The
compliance to therapy in terms of delivered dose and
treatment duration was 93%, with a complete response
rate of 90.7% [25]. More recently, SeqB approaches were
delivered with no pre-planned interruptions as in the
ACT II trial and represent, nowadays, the standard treat-
ment strategy [2]. Neverthelss, compared to the SeqB
approach, SIB potentially allows for a further reduction
in the OTT, because treatment fractions are continu-
ously delivered and different daily doses to target vol-
umes are given in the same number of fractions [1, 10].
In the attempt to investigate whether SIB may provide a
therapeutic gain, we analyzed 2 cohorts of anal cancer
patients treated with SIB and SeqB approaches. To the
best of our knowledge, this is the first study comparing
these 2 treatment strategies in terms of CFS in anal can-
cer patients. Median follow up was similar for the 2
groups (34 vs 31 months for SIB and SeqB). Focusing on
patients characteristics, the 2 cohorts were different
since the SeqB group had a significant higher proportion
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of patients with tumor of the anal margin (22.3% vs
16.1%; p < 0.0001), with positive nodes (48.5% vs 34.5%;
p = 0.0015), inguinal groin localization (35.9% vs 20.7%;
p = 0.0187), and G3 differentiation (24.1% vs 16.5%; p =
0.0003). Borderline significant difference was found for
advanced stage (IIIA-IIIB: 54.4% vs 38.0%;p = 0.0730).
Conversely, patients in the SIB group had a longer time
between biopsy and RT start (patient with time ≥ 60 days:
66.7% vs 49.5%; p = 0.0172). Median OTTs were 43 and
60 in the SIB and SeqB groups, respectively, due to the
different approaches in delivering radiation. Local re-
lapse rate was slightly higher for patients submitted to
sequential boost (SeqB: 20.4% vs SIB: 18.4%), as were re-
gional failures (SeqB: 7.8% vs SIB: 6.9%). A higher per-
centage of distant metastasis was observed in the SIB
group (14.9%) compared to the SeqB group (5.8%), even
if baseline patients characteristics were more favorable
for these patients. A slightly, but non significant, higher
colostomy rate was seen in the SeqB group (16.5% vs
13.8%). Noteworthy, in this group, one surgical procedure
was performed because of functional issues in this cohort.
After adjusting for known prognostic factors, the effect
of undergoing different treatments highlighted an AdjHR
with respect to 2-year CFS for the first 24 months of
0.95 (95%CI:0.49–1.84, p = 0.877), with an HR sup-
posedly favoring the SIB approach, even if with a confi-
dence interval containing the value 1 and thus not
considerable as statistically significant (Fig. 1). We fo-
cused on the first 2 years because, for 17 out of 103
patients in the SeqB group, we could not retrieve an up-
dated follow up (last observation time between 1 and
4 years from analysis), which could potentially affect the
CFS rates as death from any cause is considered as an
event. Interestingly, the cumulative incidence of colos-
tomies at 1 and 2 years was higher in SeqB group
(13.9%;95%CI:7.8–21.8 and 18.1%;95%CI: 10.8–27.0, re-
spectively) compared to those of the SIB group
(8.2%;95%CI:3.6–15.2 and 15.0%;95%CI: 8.1–23.9, re-
spectively). We can hypothesize that it may suggest an
explanation for the observed HR with respect to 2-year
CFS when considering the SIB group. This observation
may potentially be ascribed to the reduction in OTT
given by the SIB strategy, but others clinical factors re-
lated to both patient and tumor that were not taken into
account in the present analysis might have a consistent
role. Given the retrospective nature of the present study
and the unbalancement in terms of clinical characteris-
tics between the 2 groups, we could not assess the su-
periority of one approach over the other nor the
equivalence between them. Nevertheless, the clinical re-
sults reported within the SIB group are reassuring and
strongly suggest the equipoise between the two strat-
egies. Confirmatory prospective randomized trials would
be need to prove this hypothesis. It is also interesting to
observe that, albeit having a higher proportion of pa-
tients with high risk features in the SeqB group, no sig-
nificant outcome differences were observed. A potential
role of stage migration due to the use of inguinal SLNB
Table 3 Clinical factors potentially influencing colostomy-free survival
Univariable Multivariable SIB vs SeqB,
Propensity score adjusted
Endpoint Parameter HR 95%CI p HR 95%CI p HR 95%CI p
CSF SIB 0.90 0.53,1.54 0.703 1.18 0.67,2.09 0.560 1.15 0.65,2.04 0.621
SIB on the first 24 months 0.72 0.38,1.34 0.297 0.95 0.49,1.84 0.877 0.95 0.48,1.85 0.871
Sex (M vs F) 1.64 0.93,2.90 0.087 1.60 0.90,2.84 0.109
Age 1.02 1.00,1.04 0.119 1.02 1.00,1.04 0.124
Stage III vs I-II 1.78 1.03,3.05 0.037 1.83 1.04,3.22 0.037
G3 vs G2-G1 0.82 0.40,1.71 0.603 0.85 0.41,1.77 0.668
OS SIB 1.15 0.61,2.17 0.674 1.71 0.86,3.40 0.127 1.51 0.77,2.98 0.235
Sex (M vs F) 2.64 1.38,5.07 0.003 2.77 1.43,5.37 0.003
Age 1.03 1.00,1.06 0.043 1.03 1.00,1.06 0.031
Stage III vs I-II 2.27 1.17,4.38 0.015 2.64 1.30,5.34 0.007
G3 vs G2-G1 1.42 0.66,3.06 0.376 1.48 0.68,3.23 0.326
CIC SIB 0.71 0.34,1.47 0.352 0.87 0.41,1.85 0.713 0.85 0.39,1.83 0.675
Sex (M vs F) 0.93 0.39,2.18 0.863 0.83 0.34,2.05 0.690
Age 1.00 0.98,1.03 0.765 1.00 0.98,1.02 0.878
Stage III vs I-II 2.09 0.99,4.38 0.052 2.13 0.97,4.70 0.061
G3 vs G2-G1 0.44 0.13,1.48 0.184 0.43 0.13,1.45 0.173
Legend HR hazard ratio CI confidence interval, M vs F male vs female, UFS colostomy-free survival, OS Overall Survival, CIC Cumulative Incidence of colostomy
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in the SIB group can be pointed out to partially explain
this finding. Several series have shown the detrimental ef-
fect of a longer OTT in anal cancer patients submitted to
concurrent RT-CHT. Weber et al. have shown the a gap
longer that 37.5 days had a significant effect on clinical
outcomes in patient treated with split- course radiation
[7]. In their series patients with a longer gap had a 75%
loco-regional control rate compared to 92.3% for patients
with a shorter gap [7]. Graf et al. found that OTT > 41 days
significantly affected 5-year local control in anal cancer
patients treated with RT-CT, as the rate was 58% for pa-
tients having OTT > 41 days and 79% for those with a
OTT < 41 days (p = 0.04) [14]. This correlation was found
regardless of the treatment approach used, either
split-course or continuously delivered radiation. Pooled
data analysis of patients enrolled in the RTOG 8704 and
RTOG 9811 trials have shown a correlation between OTT
and local failure, loco-regional failure, colostomy failure
and time to failure, but not with CFS or OS [26]. In the
RTOG 92–08 trial, dose escalation up to 59.9 Gy concur-
rent to 5-FU and MMC was investigated with a
mandatory 2-week gap after 36 Gy [27]. Clinical outcomes
were poor even with a higher dose delivered, suggesting a
detrimental effect even of a short gap. Comparison be-
tween patients with similar characteristics having a
2-week gap (RTOG 9208) and those without (RTOG
8704) highlighted poorer results for patients with a longer
gap [25]. The aforementioned clinical data are explained
from a radiobiological point of view by accelerated re-
population that occurs after irradiation and may lead to a
loss in tumor control of 1–2% and of 0.4–0.6 Gy for each
day of OTT extension [28, 29]. Split-course studies dem-
onstrated that a gap longer than 15 days may consistently
affect clinical outcomes [28, 29]. Our study has some limi-
tations including its retrospective nature, the missing of
updated follow up for some patients in the SeqB cohort,
the lack of the chance to adjust results for all tumor- and
patient-related factors potentially affecting clinical out-
comes and the maximum reliability of the analysis for the
first 24 months of follow up only. Moreover the sample
size determination might not be adequate enough to de-
tect a small difference in clinical outcomes. Hence, our
data cannot be considered conclusive. Another important
limit is the lack of robust data on the toxicity profile that
did not allow us to compare the 2 approaches with respect
to this endpoint. The only toxicity endpoint analysed in
the present study was hematologic toxicity which did not
show any difference in the 2 groups with respect to ≥
G3 events. Toxicity data from the RTOG 0529 trial
showed a reduction of skin, gastro-intestinal and
hematologic toxicity for patients treated with
dose-painted IMRT compared to standard treatment.
The same treatment schedule was adopted in the SIB
group of the present study.
Nevertheless, the comparison between SeqB and SIB
approaches seems to suggest that SIB is non-inferior to
SeqB in terms of probability of being alive without a col-
ostomy in anal cancer patients, and it could be a valid
approach in this clinical setting. A potential advantage in
terms of CFS can be hypothesized for SIB due to the
shortening in OTT, but this possible finding need to be
confirmed with more robust and prospective data.
Conclusions
The present study is the first to report on comparative
outcomes of anal cancer patients treated with RT-CHT
employing a SIB strategy compared to a SeqB approach.
Given its multicenter retrospective frame, potential se-
lection biases due to the different patient and treatment
characteristics between the 2 cohorts can be outlined.
Different approaches in terms of patient care and follow
up modalities, including time to event evaluation, may
have had an influence on outcomes. Patients were given
different doses to the prophylactic nodal volumes (36 Gy
vs 42/45 Gy for the SeqB and SIB group, respectively),
even if comparable in terms of biologically equivalent
dose since given with diverse dose per fractions (1.8 Gy
vs 1.5 Gy daily). Dose to the macroscopic tumor was dif-
ferent (59.4 Gy vs 54 Gy) as delivery technique (3DCRT
vs IMRT) for the SeqB and SIB group, respectively. Pa-
tients in the SeqB group had, on average, a more ad-
vanced stage of disease presentation, while patients in
the SeqB had a longer time between biopsy and
chemo-radiation start. However, those unbalances were
properly adjusted during the analysis to obtain an
AdjHR depending mainly on treatment strategy (SIB vs
SeqB). One of the pitfall of the study was the lack of tox-
icity data. We decided not to report on toxicity because
of the retrospective nature of the study and the conse-
quent lack of reliability for these outcomes. Thus, we de-
cided to focus on CFS, OS and cumulative incidence of
colostomy, since death and colostomy were deemed
events whose detection was thought to be sufficiently re-
liable. With these robust clinical endpoints as compara-
tive parameters, both SIB and SeqB approaches proved
to be effective treatment strategies to be included in the
combined modality therapy of non-metastatic anal can-
cer patients.
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